Literature DB >> 27567878

Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons.

Ravi Rajmohan1, P Hemachandra Reddy1,2,3,4,5.   

Abstract

Amyloid-beta (Aβ) and hyperphosphorylated tau are hallmark lesions of Alzheimer's disease (AD). However, the loss of synapses and dysfunctions of neurotransmission are more directly tied to disease severity. The role of these lesions in the pathoetiological progression of the disease remains contested. Biochemical, cellular, molecular, and pathological studies provided several lines of evidence and improved our understanding of how Aβ and hyperphosphorylated tau accumulation may directly harm synapses and alter neurotransmission. In vitro evidence suggests that Aβ and hyperphosphorylated tau have both direct and indirect cytotoxic effects that affect neurotransmission, axonal transport, signaling cascades, organelle function, and immune response in ways that lead to synaptic loss and dysfunctions in neurotransmitter release. Observations in preclinical models and autopsy studies support these findings, suggesting that while the pathoetiology of positive lesions remains elusive, their removal may reduce disease severity and progression. The purpose of this article is to highlight the need for further investigation of the role of tau in disease progression and its interactions with Aβ and neurotransmitters alike.

Entities:  

Keywords:  Amyloid; neurotransmitters; synapse; tau

Mesh:

Substances:

Year:  2017        PMID: 27567878      PMCID: PMC5793225          DOI: 10.3233/JAD-160612

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  342 in total

Review 1.  Amyloid β: linking synaptic plasticity failure to memory disruption in Alzheimer's disease.

Authors:  Tao Ma; Eric Klann
Journal:  J Neurochem       Date:  2011-11-28       Impact factor: 5.372

Review 2.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

Review 3.  Modulation of LTP induction by NMDA receptor activation and nitric oxide release.

Authors:  C F Zorumski; Y Izumi
Journal:  Prog Brain Res       Date:  1998       Impact factor: 2.453

4.  Regulation of metabolite flux through voltage-gating of VDAC channels.

Authors:  T Hodge; M Colombini
Journal:  J Membr Biol       Date:  1997-06-01       Impact factor: 1.843

Review 5.  Brain excitability and connectivity of neuronal assemblies in Alzheimer's disease: from animal models to human findings.

Authors:  Marcello D'Amelio; Paolo Maria Rossini
Journal:  Prog Neurobiol       Date:  2012-07-10       Impact factor: 11.685

6.  Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice.

Authors:  Jeannie Chin; Jorge J Palop; Gui-Qiu Yu; Nobuhiko Kojima; Eliezer Masliah; Lennart Mucke
Journal:  J Neurosci       Date:  2004-05-12       Impact factor: 6.167

7.  Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's Disease.

Authors:  T Arendt; V Bigl; A Arendt; A Tennstedt
Journal:  Acta Neuropathol       Date:  1983       Impact factor: 17.088

8.  GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides.

Authors:  Christopher J Phiel; Christina A Wilson; Virginia M-Y Lee; Peter S Klein
Journal:  Nature       Date:  2003-05-22       Impact factor: 49.962

9.  {beta}-Amyloid impairs AMPA receptor trafficking and function by reducing Ca2+/calmodulin-dependent protein kinase II synaptic distribution.

Authors:  Zhenglin Gu; Wenhua Liu; Zhen Yan
Journal:  J Biol Chem       Date:  2009-02-24       Impact factor: 5.157

10.  Interleukin-1 mediates Alzheimer and Lewy body pathologies.

Authors:  W Sue T Griffin; Ling Liu; Yuekui Li; Robert E Mrak; Steven W Barger
Journal:  J Neuroinflammation       Date:  2006-03-16       Impact factor: 8.322

View more
  87 in total

1.  A Critical Assessment of Research on Neurotransmitters in Alzheimer's Disease.

Authors:  P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

2.  Ameliorative effects of astaxanthin on brain tissues of alzheimer's disease-like model: cross talk between neuronal-specific microRNA-124 and related pathways.

Authors:  Hala A Hafez; Maher A Kamel; Mohamed Y Osman; Hassan My Osman; Samar S Elblehi; Shimaa A Mahmoud
Journal:  Mol Cell Biochem       Date:  2021-02-11       Impact factor: 3.396

Review 3.  A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment.

Authors:  Brati Das; Riqiang Yan
Journal:  CNS Drugs       Date:  2019-03       Impact factor: 5.749

Review 4.  Research Progress on Alzheimer's Disease and Resveratrol.

Authors:  Yan Yan; Huihuang Yang; Yuxun Xie; Yuanlin Ding; Danli Kong; Haibing Yu
Journal:  Neurochem Res       Date:  2020-03-11       Impact factor: 3.996

5.  PhIP exposure in rodents produces neuropathology potentially relevant to Alzheimer's disease.

Authors:  Tauqeerunnisa Syeda; Rachel M Foguth; Emily Llewellyn; Jason R Cannon
Journal:  Toxicology       Date:  2020-03-10       Impact factor: 4.221

Review 6.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

7.  Sulfhydration of AKT triggers Tau-phosphorylation by activating glycogen synthase kinase 3β in Alzheimer's disease.

Authors:  Tanusree Sen; Pampa Saha; Tong Jiang; Nilkantha Sen
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-12       Impact factor: 11.205

8.  Overexpression of let-7a increases neurotoxicity in a PC12 cell model of Alzheimer's disease via regulating autophagy.

Authors:  Huizi Gu; Lan Li; Chen Cui; Zihui Zhao; Guijun Song
Journal:  Exp Ther Med       Date:  2017-08-21       Impact factor: 2.447

Review 9.  Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease.

Authors:  Jangampalli Adi Pradeepkiran; Arubala P Reddy; P Hemachandra Reddy
Journal:  Drug Discov Today       Date:  2018-11-16       Impact factor: 7.851

Review 10.  Neuropathological assessment of the Alzheimer spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2020-08-01       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.